B. Liu
Harbin Medical University · 10 works · 178 citations · h-index 4
Top works
- LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial
- Platelet count predicts prognosis in operable non-small cell lung cancer
- Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma
- A study of circulating anti-CD25 antibodies in non-small cell lung cancer
- 5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study
- 513MO Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysis
- 991MO Prophylactic management of dermatologic adverse events with amivantamab + lazertinib treatment in 1L EGFR-mutated NSCLC: COCOON asian subset analysis
- Mechanism of IL-4 mediated RPL19 promoting malignant progression in HER2 positive breast cancer
- 928MO ARTEMIS-001: A phase I study of HS-20093 (GSK5764227) in patients with non-small cell lung cancer (NSCLC)
- 988P Analysis of MET amplification (METamp) with FISH and NGS method in SACHI trial